Jan-Philipp Weber,Martin Wermke
Jan-Philipp Weber
Background: Although the treatment and prognosis of many solid tumor types in the metastatic situation could be considerably improved during the last decade, for a long time no significant progress in the treatment of sma...
Matthias Scheffler,Sebastian Michels,Lucia Nogova
Matthias Scheffler
Non-small cell lung cancer (NSCLC) has made a remarkable development in recent decades with respect to its perception. In the late 1990s it was the "problem child" as the main cause of cancer with increasing tendencies, especially in women ...
Sabine Hatzfeld,Bärbel Söhlke
Sabine Hatzfeld
The image of lung cancer as a disease of 70-year-old smokers is incomplete. The number of younger people and nonsmokers, who often carry mutations that can be successfully treated, is far from being low. For those affected, targeted treatme...
[Cytopathology and molecular diagnostics of non-small cell lung cancer (NSCLC)] [0.03%]
非小细胞肺癌(NSCLC)的细胞病理学和分子诊断学
Jana Fassunke,Marianne Engels,Sonja Meemboor et al.
Jana Fassunke et al.
Cytological specimens from endobronchial aspirates and pleural effusions are frequently used materials in the diagnostics of non-small cell lung cancer (NSCLC). In the same way as histological samples from endobronchial and transbronchial b...
[Treatment of early and locally advanced stages of non-small cell lung cancer] [0.03%]
早期和局部晚期非小细胞肺癌的治疗
Marcel Wiesweg,Wilfried E Eberhardt,Martin Schuler et al.
Marcel Wiesweg et al.
Treatment concepts for patients with localized and locally advanced non-small cell lung cancer (NSCLC) are based on local treatment, surgery and/or radiotherapy, with curative intent. An adjuvant systemic treatment is added after primary re...
Nikolaj Frost,Martin Reck
Nikolaj Frost
Within a few years the introduction of immune checkpoint inhibitors (ICI) fundamentally changed the treatment landscape of patients with metastatic non-small cell lung cancer (NSCLC) and improved survival for a relevant proportion of patien...
[ZSE-DUO - dual guidance structure at the centre for rare diseases] [0.03%]
[ZSE-DUO - 罕见病中心的双重指导结构]
C Schippers,D Volk,M de Zwaan et al.
C Schippers et al.
Background: Patients with an unclear diagnosis and suspected rare disease pose special challenges to physicians, among others. Aim of the study (research ...
[Coagulation diagnostics in the clinical routine-part 2 : Monitoring of anticoagulation treatment, new-onset thrombocytopenia and thrombophilia] [0.03%]
凝血诊断在临床常规应用之二：抗凝治疗监测、新发血小板减少症和易栓症
Michael Metze,Martin Platz,Christian Pfrepper et al.
Michael Metze et al.
Monitoring of vitamin K antagonist treatment with the international normalized ratio (INR) is obligatory, whereas this only applies to direct oral anticoagulants (DOAC) or low molecular weight heparin in the context of selected clinical sce...
[Empagliflozin in the treatment of heart failure with preserved ejection fraction] [0.03%]
恩格列净治疗射血分数保留的心力衰竭
C Morbach,S Frantz,S Nitschmann
C Morbach
[SER-109: oral microbiome therapy for recurrent Clostridioides difficile infections : SER-109 versus Placebo in the Treatment of Adults with Recurrent Clostridium Difficile Infection (ECOSPOR III)] [0.03%]
SER-109：用于复发性难辨梭菌感染的口腔微生物疗法：SER-109与安慰剂治疗成人复发性艰难梭菌感染（ECOSPOR III）
A Stallmach,S Nitschmann
A Stallmach